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Abstract
Background: Occult Hepatitis C virus (HCV) infection is a new pathological entity characterized by presence of liver disease
and absence or very low levels of detectable HCV-RNA in serum. Abnormal values of liver enzymes and presence of
replicative HCV-RNA in peripheral blood mononuclear cells are also observed. Aim of the study was to evaluate occult HCV
occurrence in a population unselected for hepatic disease.
Methodology/Principal Findings: We chose from previous epidemiological studies three series of subjects (n=276, age
range 40–65 years) unselected for hepatic disease. These subjects were tested for the presence of HCV antibodies and HCV-
RNA in plasma and in the peripheral blood mononuclear cells (PBMCs) by using commercial systems. All subjects tested
negative for HCV antibodies and plasma HCV-RNA and showed normal levels of liver enzymes; 9/276 patients (3.3%) were
positive for HCV-RNA in PBMCs, identifying a subset of subjects with potential occult HCV infection. We could determine the
HCV type for 8 of the 9 patients finding type 1a (3 patients), type 1b (2 patients), and type 2a (3 patients).
Conclusions: The results of this study show evidence that occult HCV infection may occur in a population unselected for
hepatic disease. A potential risk of HCV infection spread by subjects harbouring occult HCV infection should be considered.
Design of prospective studies focusing on the frequency of infection in the general population and on the clinical evolution
of occult HCV infection will be needed to verify this unexpected finding.
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Introduction
Occult Hepatitis C virus (HCV) infection has been defined
[1–5] as a pathological entity displaying different clinical features
from typical HCV infection. HCV infection is routinely diagnosed
and monitored by the detection of HCV antibodies and/or HCV-
RNA in plasma or serum. Subjects affected by occult HCV
infection test negative for HCV-RNA in serum, but they are
HCV-RNA positive in liver biopsies and may display abnormal
values of liver enzymes. Occult HCV infection may occur under
two different clinical situations: patients may show either
negativity for both serum HCV antibodies and HCV-RNA with
abnormal liver function tests, or positivity for HCV antibodies and
no detectable serum HCV-RNA with normal liver enzymes, due
to clearance of infection [5–8]. Furthermore, the presence of low
levels of HCV genomes (silent HCV infections) in different
pathological setting was reported, mainly in subjects with a
previous history of HCV related disease [6,9–12]. Among patients
with cryptogenic chronic hepatitis, those with occult HCV
infection had more liver inflammation and fibrosis than those
without occult HCV infection [1]. In occult HCV patients, the
presence of HCV-RNA was also identified in peripheral blood
mononuclear cells (PBMCs) [1,2,13], which represent alternative
extrahepatic site of HCV replication [2,4,14,15] proposed as a
source of recurrent HCV infection after liver transplantation
[2,16,17]. Different immune cell subsets (e.g. CD4+ and CD8+ T
lymphocytes, B cells and monocytes) can be HCV infected. HCV
may be also confined to a specific immune cell subtype with risk of
low analytical HCV-RNA detection. New technologies employing
multiple mitogens stimulation has been improved to avoid false
negative results [13,18,19]. Although the mechanism of HCV
replication is not completely understood, viral replication is
assumed to involve the synthesis of a negative-strand RNA
molecule (antigenomic HCV-RNA) that acts as a template for
production of a positive-strand RNA molecule (genomic HCV-
RNA) [2,15,20]. The detection of the antigenomic HCV-RNA
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replication. Both the genomic and the antigenomic HCV-RNA
strands have been detected in PBMCs of patients with occult HCV
infection [2,21], supporting the hypothesis that HCV is able to
replicate in these cells.
In the frame of a case-control study nested in the EPIC
(European Prospective Investigation into Cancer and Nutrition)
Italy cohort [22,23], designed to evaluate the etiological role of
viruses (HCV included) in the occurrence of Non-Hodgkin’s
Lymphoma, we were surprised to find that 7/176 of the control
subjects displayed features characteristic of occult HCV infection
(Richiardi et al submitted). These subjects were disease free when
enrolled and tested negative for both HCV antibodies and plasma
HCV-RNA, but they resulted positive for HCV-RNA in the
PBMCs. Therefore, occult HCV infection may occur in the
general population apparently disease free. The presence of viral
replicative ability in PBMCs could represent a potential risk of
HCV spread through transfusion, haemodialysis [4,24], or of liver
disease evolution (e.g. liver neoplasia) in occult HCV infected
subjects [4,25].
To support the results obtained in control samples from the
EPIC Italy cohort study (Richiardi et al. submitted), we analysed
two additional independent series for detection of HCV antibodies
and HCV-RNA both in plasma and in PBMCs.
Results
All subjects in the study had normal levels of ALT (range from 5
to 17 IU/L) and AST (range from 5 to 25 IU/L) and resulted
negative for HCV antibodies and viremia. All RNA extracted
samples resulted positive at the b-actin amplification, confirming
adequacy for the HCV PCR analyses. Considering all study series
(‘‘EPIC Italy’’, ‘‘Turin Case-Control Bladder Cancer’’, ‘‘Cervical
Cancer Screening’’), we found that 9 out of the 276 (3.3%; 95%
CI: 1.5–6%) subjects testing negative for HCV antibodies and
viremia were positive for HCV-RNA in their PBMCs. HCV-RNA
positivity was confirmed by direct sequencing matching the 59-
UTR region of HCV genome according to the Blast sequence. As
summarized in Table 1, 7/176 (4.0%) subjects in the EPIC Italy
series and 2/60 (3.3%) subjects in the Cervical Cancer Screening
series, were positive for HCV-RNA in PBMCs. All (40/40, 100%)
subjects in the Turin Case-Control Bladder Cancer series tested
negative. HCV genotypes were determined for 8 of 9 specimens
resulting HCV type 1a, 1b and 2a (Table 2), one sample was not
genotyped since a very weak PCR fragment was detected.
Discussion
At present, occult HCV infection has been described in relation
to hepatic diseases, and data on the frequency of HCV-RNA in
the PBMCs of the general population are unknown.
We identified subjects apparently free of liver disease, since
testing normally for liver enzymes and negative for serological
HCV markers, which unexpectedly showed potential occult HCV
infection features.
Negative serological results were unlikely due to low sensitivity,
as the tests employed to detect HCV antibodies and circulating
virus have been extensively reported to have high reliability, with a
98.8% sensitivity and a 100% specificity [1]. If these values of
specificity and sensitivity are applied to a prevalence of 2.7% of
detection of HCV antibodies found in the Italian population [26]
the Negative Predictive Value (NPV according to Bayes theorem)
is 0.99966, and the probability that 9 or more of the 276 negative
results were false negatives is virtually zero (4.1
215, Exact Binomial
Probability).
Despite the most prevalent HCV genotype in Italy [26] is 1b,
interestingly we identified the presence of different HCV
genotypes (1a, 1b, 2a) in the PBMCs of our study population.
Similar results were as well observed in other series of subjects
considered to be clinically and serologically cleared of HCV
infection [6].
The unexpected result of this study raises the issue of occult
HCV infection frequency in the general population and its
potential implications on the safety of medical procedures and the
onset of liver disease. Subjects with occult HCV infection may not
harbor detectable circulating virions, but they could be still
potentially infectious, as PBMCs have been demonstrated to be
permissive for viral replication [4].
The potential risk for HCV spread from occult HCV subjects
through blood transfusions and hemodialysis units should be
considered [27]. Despite advances in the screening procedures for
infectious agents in blood from donors, the risk of transmission via
transfusion of viral, bacterial, and protozoal infections, as well as
from newly emerging diseases, remains [28]. Despite approaches
to leukocyte-related risk reduction as the leukodepletion [28–31],
the efficacy in reducing the risk of transmitting infectious agents is
still under discussion for some viruses (cytomegalovirus, human
herpesvirus-8, Epstein–Barr virus, human T-cell leukemia/lym-
phoma virus) and prions [28,29]. Therefore, those donors who
carry HCV in their PBMCs may be overlooked by current
screening strategies [4].
Moreover, since it has been observed that very low-level of
HCV-RNA may persist in the PBMCs for many years represent-
ing a potential risk for the recurrence of infection, the clinical
potential in hepatocarcinogenesis should be evaluated [9,32]. With
this study we could not deeply evaluate the implications of
persistent HCV-RNA in PBMCs on liver disease evolution since
no information was available about the follow-up of the studied
subjects. Neither analysis about the viral load were performed due
to limited amount of sample. As well, limited amount of both
Table 1. HCV detection in three series of subjects.
Subjects
Number
of
subjects
HCV
antibodies
(%)
HCV –RNA
plasma
(%)
HCV –RNA
PBMCs
(%)
a
All series
All subjects 276 0 (0) 0 (0) 9 (3.3%)
Men (age range:
36–65 years)
111 0 (0) 0 (0) 3 (2.7%)
Women (age range:
39–76 years)
165 0 (0) 0 (0) 6 (3.6%)
EPIC Italy-cohort series
All subjects 176 0 (0) 0 (0) 7 (4.0%)
Men (age range:
36–65 years)
71 0 (0) 0 (0) 3 (4.2%)
Women (age range:
39–76 years)
105 0 (0) 0 (0) 4 (3.8%)
Turin Case-Control Bladder Cancer series(controls)
Men (age range:
42–66 years)
40 0 (0) 0 (0) 0 (0%)
Cervical Cancer Screening series
Women (age range:
46–61 years)
60 0 (0) 0 (0) 2 (3.3%)
aPBMCs, peripheral blood mononuclear cells.
doi:10.1371/journal.pone.0008128.t001
Occult HCV & Normal Population
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did not allow performing of techniques developed in recent years
as PBMCs mitogen stimulation [6] and ultracentrifugation which
is mainly performed with at least 2 ml of plasma [33]. However,
the fact that we found HCV RNA positivity in PBMCs despite the
limited amount may result in an underestimate of the phenom-
enon, which further strengthens the relevance of our results.
Whenever we had found a HCV RNA positivity after ultracen-
trifugation of plasma from the same subjects, the final result of
occult HCV would not be altered [7].
The results of this study show evidence that occult HCV
infection may occur in a population unselected for hepatic disease.
A potential risk of HCV infection spread by subjects who
unknowingly may carry occult HCV infection and of liver disease
onset should be considered.
Design of prospective studies focusing on the prevalence and on
the clinical evolution of occult HCV infection in the general
population will be needed to verify this unexpected finding, as well
as the analysis of HCV-RNA replication potential, the identifica-
tion of HCV genotypes involved in occult HCV infection, and the
evolution of liver disease.
Materials and Methods
Ethic Statement
Ethic statement was not required for this specific study. All
participants recruited, controls included, donated blood samples in
previous epidemiological studies, following written informed
consent given to principal investigators. These blood samples
were re-used, since previous ethical approval included enabling
other non-specified tests to be carried out on the biological samples
supplied.
Study Population
The present study was performed including a total of 276
subjects (111 men and 165 women) as sample of the general
population. All subjects aged between 40 and 65, were apparently
liver disease free at recruitment, and were enrolled in the frame of
three different epidemiologic studies previously approved by local
ethic committees: EPIC Italy cohort (protocol number: 96/01)
[22,23], Turin Case-Control Bladder Cancer Study (protocol
number: CEI/174)[34], Cervical Cancer Screening (registration
number: ISRCTN81678807) [35] (Table 1).
All participants in the studies, following written informed
consent given to principal investigators, donated a blood sample,
which was collected and fractioned (red blood cells, buffy-coat,
serum and plasma) on the day of enrolment and snap frozen in
liquid nitrogen or at 280uC.
EPIC Italy cohort series: The European Prospective Investiga-
tion into Cancer and Nutrition (EPIC) included healthy subjects
enrolled in 10 European countries. The EPIC Italy cohort
involved 5 centres (Turin, Varese, Florence, Naples, and Ragusa)
with a total of 47,000 subjects enrolled between 1992 and 1998. In
the present study, we included 176 subjects randomly selected as
controls for the Non-Hodgkin’s Lymphoma study (Richiardi et al.
submitted) from the eligible members of the EPIC Italy cohort: 39
from Turin, 74 from Varese, 42 from Florence, 11 from Naples,
and 10 from Ragusa. These controls were matched to the
corresponding lymphoma case on sex, centre, age (within 5 years),
and period of collection of the blood sample (within 90 days). They
were a sample of the general population, although blood donors
and attendants to screening programs were over-sampled.
Detailed information for each volunteer about diet and life-style
habits, anthropometric measurements and residential and occu-
pational history was collected.
Turin Case-Control Bladder Cancer Study series: Hospital-
based case-control investigations at two urology departments in S.
Giovanni Battista Hospital in Turin, Italy. Subjects with newly
diagnosed bladder cancer in the Turin metropolitan area were
recruited as cases. Subjects with benign diseases, mainly prostatic
hyperplasia and cystitis (all newly diagnosed), and patients treated
at the medical and surgical departments for hernias, vasculopa-
thies, diabetes, heart failure, asthma or other benign diseases (none
was represented in .10%), were recruited from the medical and
surgical departments of the same hospital as controls. Patients with
cancer other than bladder, liver or renal disease, and smoking-
related conditions were excluded. In the present study were
included 40 men (aged between 40 and 65) consecutively recruited
as controls between 2001 and 2003.
Cervical Cancer Screening series: Italian project designed in the
frame of Cervical Cancer Screening Programmes to study
papillomavirus infection, frequency, prevalence, and implication
in cervical lesions progression. In the present study, we included 60
women (aged between 40 and 65) consecutively recruited in Turin
between 2002 and 2004 which gave consent to donate a blood
sample.
Table 2. Characteristic of subjects showing occult HCV.
Patient Sex Age ALT/AST* HCV antibody HCV-RNA plasma HCV-RNA PBMCs HCV Genotyping
1M 5 1 2/22 2 + 1a
2M 6 0 2/22 2 + n.d.
3F 4 6 2/22 2 + 1b
4F 5 2 2/22 2 + 1b
5F 5 6 2/22 2 + 2a
6M 4 1 2/22 2 + 2a
7F 5 4 2/22 2 + 2a
8F 5 5 2/22 2 + 1a
9F 4 7 2/22 2 + 1a
*: 2/2 indicates normal values below 50 IU/L and 35 IU/L for men and women respectively for ALT, and below 40 IU/L and 32 IU/L for men and women respectively for
AST determination.
n.d.: the amplification resulting in a very weak fragment and sequence analysis did not succeed.
doi:10.1371/journal.pone.0008128.t002
Occult HCV & Normal Population
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Quantitative levels of alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) in plasma were evaluated by
using an UV test on Roche automated clinical chemistry analyzer
(Cobas, Roche/Hitachi Modular analyzers, North America,
USA). This method has been standardized according to the
original International Federation of Clinical Chemistry (IFCC)
formulation. The expected normal values according to IFCC were
up to 50 IU/L and up to 35 IU/L for men and women
respectively for ALT, and up to 40 IU/L and up to 32 IU/L for
men and women respectively for AST determination. The
analytical sensitivity is 4 IU/L for both the determinations, and
the measuring range is 4–600 IU/L and 4–800 IU/L for ALT and
AST respectively.
HCV Antibodies Research
Detection of HCV antibodies was performed by a commercial
enzyme immunoassay test of third-generation (ORTHO HCV
3.0 – commercialized by Dia Sorin, Saluggia, Italy) following the
manufacturer instructions. Samples showing optical densities
above the cut off value were considered positive. The sensitivity
and specificity of the test were estimated of 98.8% and 100%
respectively [1,36].
HCV RNA Extraction and Detection
Total RNA was isolated from 150 mL of buffy-coat and 150 mL
plasma using SV total RNA Isolation system (Promega, Madison,
Wi, USA) and EXTRAgene (Amplimedical, Turin, Italy)
respectively, following the manufacturer instructions. In
150 mL of buffy-coat there was a range between 10
6 and 10
7
cells: they were washed three times by using SV RNA Red Blood
Cell Lysis Solution (Promega, Madison, Wi, USA) in order to
avoid contaminants carry over. Adequacy of RNA extraction was
evaluated by retro-transcription of 5 mLb yt h eR e v e r s e
Transcription System (Promega) to cDNA and amplification of
a 171 bp fragment of the b-actin gene (primer forward 59-CCC-
CGCGAGCACAGA-39 and reverse 59-CCACGATGGAGGG-
GAAGAC-39) according to Lossos et al, 2003 [37]. Detection of
HCV-RNA was performed by a commercial RT-nested PCR
system (AlfaWasserman,Milan, Italy) usingprimers targeting the
59UTR region of the HCV genome, reagents and controls
included in the kit. According to the manufacturer instructions,
five microliters of extracted RNA were in single step reverse
transcribed and amplified as follows: 30 min at 42uC( r e t r o -
transcription); 5 min at 95uC; 25 s at 94uC, 20 s at 50uC, 40 s at
72uC for 30 cycles; and a final extension of 5 min at 72uC. Three
microliters of RT-PCR reaction were added to the second step
(nested) PCR and amplified for other 30 cycles, using the same
cycling conditions of the first step. Amplicons were analysed on
2% agarose gel stained with ethidium bromide and visualized
by ultraviolet transillumination. The presence of a 187 bp
amplification fragment indicate HCV-RNA positivity in the
sample. Synthetic HCV-RNA corresponding to 59UTR region,
HCV negative human serum and RNA-free sample were
included as positive and negative controls respectively in each
PCR run. The sensitivity of this test was up to 50 genome
equivalents (6 IU/ml). All positive samples were repeated for
confirmation in different runs of PCR amplification to exclude
contamination occurrence.
We used plasma rather than serum because prior RT-PCR
studies showed a higher sensitivity when the analyses were
performed with plasma [15,38].
HCV Genotyping
The positive PCR products of the 59UTR region were excised
from the gel and purified with the ‘‘PCR Clean-up Gel Extraction
Kit’’ (Macherey-Nagel, Dueren, Germany). Direct sequencing was
carried out using the Big Dye Terminator Cycle Sequencing
Ready Reaction Kit (Applera, Monza, Italy), and sequence
analysis was performed with the ABI 310 automated capillary
system (Applera, Monza, Italy), following the manufacturer
instructions. Sequences were analyzed with the BLAST Software
(http://www.ncbi.nlm.nih.gov/BLAST). All HCV genotypes were
defined with a query coverage $98%, analyzing at least 170
nucleotides of the target sequence.
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